265 related articles for article (PubMed ID: 31186439)
1. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
[TBL] [Abstract][Full Text] [Related]
2. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
[TBL] [Abstract][Full Text] [Related]
3. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
[TBL] [Abstract][Full Text] [Related]
4. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
5. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.
Liu YL; Ford HE; Druce MR; Minnion JS; Field BC; Shillito JC; Baxter J; Murphy KG; Ghatei MA; Bloom SR
Int J Obes (Lond); 2010 Dec; 34(12):1715-25. PubMed ID: 20531351
[TBL] [Abstract][Full Text] [Related]
7. The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats.
Stein LM; McGrath LE; Lhamo R; Koch-Laskowski K; Fortin SM; Skarbaliene J; Baader-Pagler T; Just R; Hayes MR; Mietlicki-Baase EG
Am J Physiol Regul Integr Comp Physiol; 2021 Aug; 321(2):R250-R259. PubMed ID: 34259025
[TBL] [Abstract][Full Text] [Related]
8. Combination of Lorcaserin and GLP-1/glucagon Coagonist Improves Metabolic Dysfunction in Diet Induced-obese Mice.
Patel V; Joharapurkar A; Kshirsagar S; Patel M; Savsani H; Bahekar R; Jain M
Drug Res (Stuttg); 2020 Aug; 70(8):376-384. PubMed ID: 32645724
[TBL] [Abstract][Full Text] [Related]
9. Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli.
Züger D; Forster K; Lutz TA; Riediger T
Physiol Behav; 2013 Mar; 112-113():61-9. PubMed ID: 23438370
[TBL] [Abstract][Full Text] [Related]
10. Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.
Sun X; Yang D; Li Y; Shi J; Zhang X; Yi T
Peptides; 2024 Jul; 177():171203. PubMed ID: 38582303
[TBL] [Abstract][Full Text] [Related]
11. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.
Larsen PJ; Fledelius C; Knudsen LB; Tang-Christensen M
Diabetes; 2001 Nov; 50(11):2530-9. PubMed ID: 11679431
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.
Roth JD; Coffey T; Jodka CM; Maier H; Athanacio JR; Mack CM; Weyer C; Parkes DG
Endocrinology; 2007 Dec; 148(12):6054-61. PubMed ID: 17761760
[TBL] [Abstract][Full Text] [Related]
14. Exogenous glucagon-like peptide-1 reduces body weight and cholecystokinin-8 enhances this reduction in diet-induced obese male rats.
Mhalhal TR; Washington MC; Newman K; Heath JC; Sayegh AI
Physiol Behav; 2017 Oct; 179():191-199. PubMed ID: 28647503
[TBL] [Abstract][Full Text] [Related]
15. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control.
Ladenheim EE
Curr Opin Endocrinol Diabetes Obes; 2012 Feb; 19(1):13-8. PubMed ID: 22157396
[TBL] [Abstract][Full Text] [Related]
17. Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats.
Trevaskis JL; Lei C; Koda JE; Weyer C; Parkes DG; Roth JD
Obesity (Silver Spring); 2010 Jan; 18(1):21-6. PubMed ID: 19543217
[TBL] [Abstract][Full Text] [Related]
18. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
Elfers CT; Chichura KS; Ashlaw EF; Chepurny OG; Holz GG; Doyle RP; Roth CL
Clin Nutr; 2024 Jul; 43(7):1782-1790. PubMed ID: 38861891
[TBL] [Abstract][Full Text] [Related]
19. Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents.
Roth JD; D'Souza L; Griffin PS; Athanacio J; Trevaskis JL; Nazarbaghi R; Jodka C; Athanacio J; Hoyt J; Forood B; Parkes DG
Diabetes Obes Metab; 2012 Jul; 14(7):608-15. PubMed ID: 22276636
[TBL] [Abstract][Full Text] [Related]
20. The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy.
Larsen AT; Sonne N; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2020 Jul; 374(1):74-83. PubMed ID: 32317372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
